Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral HRS5685 in Healthy Subjects

NCT05328583 is registered in ClinicalTrials.gov with RetroLead (Shanghai) BioPharma Co., Ltd. as lead sponsor.

NCT NCT05328583
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05328583 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral HRS5685 in Healthy Subjects
Lead sponsor
RetroLead (Shanghai) BioPharma Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
April 15, 2022
Completion date
March 10, 2023
Enrollment
64 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

human immunodeficiency virus-1 (hiv-1) infection